Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: The multi-ethnic study of atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 4, 2015, Pages 996-1001

  Guan, Weihua ^a   Cao, Jing ^b   Steffen, Brian T ^b   Post, Wendy S ^c   Stein, James H ^d   Tattersall, Mathew C ^d   Kaufman, Joel D ^e   McConnell, Joseph P ^f   Hoefner, Daniel M ^f   Warnick, Russell ^f   Tsai, Michael Y ^b  

^a Boston University Medical Campus   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f Health Diagnostics Laboratory   (United States)

Author keywords

continental population groups; coronary disease; lipoprotein(a); risk factor

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL LABORATORY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; HIGH RISK PATIENT; HUMAN; IMMUNOASSAY; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MIDDLE AGED; MORBIDITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; SEX RATIO; TURBIDIMETRIC IMMUNOASSAY; TURBIDIMETRY; AFRICAN AMERICAN; ANCESTRY GROUP; ASIAN AMERICAN; BLOOD; CAUCASIAN; CHINA; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY DISEASE; DYSLIPIDEMIAS; EPIDEMIOLOGY; ETHNOLOGY; HEALTH DISPARITY; HISPANIC; MULTICENTER STUDY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TIME FACTOR; UNITED STATES; VERY ELDERLY;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ASIAN AMERICANS; BIOMARKERS; CHINA; CONTINENTAL POPULATION GROUPS; CORONARY DISEASE; DYSLIPIDEMIAS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH STATUS DISPARITIES; HISPANIC AMERICANS; HUMANS; IMMUNOASSAY; INCIDENCE; LIPOPROTEIN(A); MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 84933519974     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.304785     Document Type: Article

References (25)

1. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129: S49-S73.
2. Nordestgaard BG, Chapman MJ, Ray K, et al; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844-2853. doi: 10.1093/eurheartj/ehq386.
3. Kronenberg F, Kronenberg MF, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, Egger G, Utermann G, Willeit J. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation. 1999;100:1154-1160.
4. Virani SS, Brautbar A, Davis BC, Nambi V, Hoogeveen RC, Sharrett AR, Coresh J, Mosley TH, Morrisett JD, Catellier DJ, Folsom AR, Boerwinkle E, Ballantyne CM. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2012;125:241-249. doi: 10.1161/CIRCULATIONAHA.111.045120.
5. Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, Mora S. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation. 2014;129:635-642. doi: 10.1161/CIRCULATIONAHA.113.004406.
6. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009; 302: 412-423.
7. Schreiner PJ, Morrisett JD, Sharrett AR, Patsch W, Tyroler HA, Wu K, Heiss G. Lipoprotein[a] as a risk factor for preclinical atherosclerosis. Arterioscler Thromb. 1993;13:826-833.
8. Schreiner PJ, Heiss G, Tyroler HA, Morrisett JD, Davis CE, Smith R. Race and gender differences in the association of Lp(a) with carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 1996;16:471-478.
9. Marcovina S, Koschinsky M. Lipoprotein (a): structure, measurement, and clinical significance. In: Rifai N, Warnick KF, Dominiczak M, eds. Handbook of Lipoprotein Testing. Washington, DC: AACC Press; 2000:345-385.
10. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331-2339. doi: 10.1001/jama.2009.801.
11. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90:52-60. doi: 10.1172/JCI115855.
12. Mooser V, Scheer D, Marcovina SM, Wang J, Guerra R, Cohen J, Hobbs HH. The Apo(a) gene is the major determinant of variation in plasma Lp(a) levels in African Americans. Am J Hum Genet. 1997;61:402-417. doi: 10.1086/514851.
13. Howard BV, Le NA, Belcher JD, Flack JM, Jacobs DR Jr, Lewis CE, Marcovina SM, Perkins LL. Concentrations of Lp(a) in black and white young adults: relations to risk factors for cardiovascular disease. Ann Epidemiol. 1994;4:341-350.
14. Tsimikas S, Clopton P, Brilakis ES, Marcovina SM, Khera A, Miller ER, de Lemos JA, Witztum JL. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation. 2009;119:1711-1719. doi: 10.1161/CIRCULATIONAHA.108.836940.
15. Banerjee D, Wong EC, Shin J, Fortmann SP, Palaniappan L. Racial and ethnic variation in lipoprotein (a) levels among Asian Indian and Chinese patients. J Lipids. 2011;2011:291954. doi: 10.1155/2011/291954.
16. Kamboh MI, Rewers M, Aston CE, Hamman RF. Plasma apolipoprotein A-I, apolipoprotein B, and lipoprotein(a) concentrations in normoglycemic Hispanics and non-Hispanic whites from the San Luis Valley, Colorado. Am J Epidemiol. 1997;146:1011-1018.
17. Haffner SM, Gruber KK, Morales PA, Hazuda HP, Valdez RA, Mitchell BD, Stern MP. Lipoprotein(a) concentrations in Mexican Americans and non-Hispanic whites: The San Antonio Heart Study. Am J Epidemiol. 1992;136:1060-1068.
18. Guyton JR, Dahlen GH, Patsch W, Kautz JA, Gotto AM Jr. Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B. Arteriosclerosis. 1985;5:265-272.
19. Willeit P, Kiechl S, Kronenberg F, Witztum JL, Santer P, Mayr M, Xu Q, Mayr A, Willeit J, Tsimikas S. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol. 2014;64:851-860. doi: 10.1016/j. jacc.2014.03.061.
20. Hobbs GA, Kaplan IV, Levinson SS. Mechanized lipoprotein(a) assay as a marker for coronary artery disease illustrates the usefulness of high lipoprotein(a) levels. Clin Chim Acta. 1998;274:1-13.
21. Faraggi D, Simon R. A simulation study of cross-validation for selecting an optimal cutpoint in univariate survival analysis. Stat Med. 1996;15:2203-2213. doi: 10.1002/ (SICI)1097-0258(19961030)15:20<2203::AID-SIM357>3.0.CO;2-G.
22. Yang WX, Yang Z, Wu YJ, Qiao SB, Yang YJ, Chen JL. Factors associated with coronary artery disease in young population (age ≤ 40): analysis with 217 cases. Chin Med Sci J. 2014;29:38-42.
23. Liang XH, Huang CZ. [Detection of serum Lp(a) level of coronary heart disease and its clinical significance]. Hunan Yi Ke Da Xue Xue Bao. 2001;26:227-228.
24. Qin SY, Liu J, Jiang HX, Hu BL, Zhou Y, Olkkonen VM. Association between baseline lipoprotein (a) levels and restenosis after coronary stenting: meta-analysis of 9 cohort studies. Atherosclerosis. 2013;227: 360-366. doi: 10.1016/j.atherosclerosis.2013.01.014.
25. Marcovina SM, Albers JJ, Scanu AM, Kennedy H, Giaculli F, Berg K, et al. Use of a reference material proposed by the international federation of clinical chemistry and laboratory medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem 2000;46:1956-67.